[Companies at a Crossroads] DT&CRO No. 6: Chairman Park Chae-gyu Alone Pockets 'Special Bonus' Amid Liquidity Crisis
Predicted impact: Medium
Chairman's special bonus during a liquidity crisis at a small company; governance concern, no amount given.
Dt&Cro디티앤씨알오
383930 · KOSDAQ · ₩383930 · 디티앤씨알오
₩2,030▼ ₩65 (3.10%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −30.72%
- Market cap
- ₩26B
- Enterprise value
- ₩63B
- P/E
- —
- P/B
- 3.6×
- Dividend yield
- 0.0%
- ROE
- −237.1%
- Net margin
- −34.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−50.7% from the high
₩1,430Today: ₩2,010 – ₩2,215₩4,115
Returns
- 1W−16.3%
- 1M+25.5%
- 3M+19.1%
- 6M−43.1%
- YTD−21.6%
- 1Y−30.7%
- Volume today
- 45,313
- 0.3× the 20-day average
- Traded today
- ₩93M
- Listed shares
- 12,784,128
- EPS (12 months)
- −₩1,337
- Earnings yield −65.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumFlat24.1% over the last month; the price is below its 20-day average.
- News impactSome3 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Dt&Cro stock overview
Dt&Cro (디티앤씨알오, KRX: 383930) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Full-Service contract research organization (CRO) that provides non-clinical and clinical trial services to pharmaceutical, medical device, health functional food, cosmetics and chemical companies, as well as research institutions. Its shares closed at ₩2,030 on Oct 27, 2026, down 3.10% on the day, giving it a market value of ₩26B.
Key facts
- Market cap
- ₩26B
- Sector
- Biotech & Pharma
- Latest price change
- −3.10%
- As of
- Oct 27, 2026
- Main business
- The company is a Full-Service contract research organization (CRO) that provides non-clinical and clinical trial services to pharmaceutical, medical device, health functional food, cosmetics and chemical companies, as well as research institutions.
Quick answers about Dt&Cro
- What does Dt&Cro do?
- The company is a Full-Service contract research organization (CRO) that provides non-clinical and clinical trial services to pharmaceutical, medical device, health functional food, cosmetics and chemical companies, as well as research institutions. S. FDA approval, and it also runs an analysis center offering PK/TK and bioanalytical services.
- What is the market cap of Dt&Cro?
- The market capitalisation of Dt&Cro was ₩26B at the close on Oct 27, 2026.
- Who are the largest shareholders of Dt&Cro?
- According to the latest official filings, the largest reported holders are Yujin Mid-Cap Value-Up Private Equity Fund (38.75%, as of Feb 26, 2026); DT&C (30.74%, as of Aug 8, 2025); Seol Jeong-won (0.00%, as of Dec 26, 2024).
- When is the next earnings report from Dt&Cro?
- Korean companies rarely announce results dates in advance. Based on when Dt&Cro filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Full-Service contract research organization (CRO) that provides non-clinical and clinical trial services to pharmaceutical, medical device, health functional food, cosmetics and chemical companies, as well as research institutions. Its services span the drug development cycle, from early strategy and non-clinical efficacy and safety (toxicity) testing to clinical trials (Phases 1 to 4), bioequivalence studies and consulting for U.S. FDA approval, and it also runs an analysis center offering PK/TK and bioanalytical services. The company operates in Korea and serves domestic and overseas clients.
Written by AI from the company's latest annual report.
- Korean name
- 디티앤씨알오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 박채규
- Founded
- Apr 2017
- Listed
- Nov 2022
- Listed shares
- 12,784,128
- Fiscal year ends
- Month 12
- Website
- www.dtncro.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
DT&CRO Says It Will Digitize Non-Clinical Toxicity Assessment, Building 'AI Pathology' Early Next Year
Predicted impact: Low· Actual: −9.7% vs sector, volume 0.6× normal (5 trading days)
Plan to digitize toxicity testing; no revenue or size figures given.
[Companies at a Crossroads] DT&C RO⑤ Did the suspicious 'contract assets' time bomb go off? Losses of several billion won occur
Predicted impact: Medium· Actual: −23.5% vs sector, volume 0.9× normal (5 trading days)
Suspicious contract assets lead to losses of several billion won; small-cap accounting concern.
Recent filings
See all- Amended: Lawsuit filed or ruledOct 7, 2026
- Lawsuit filed or ruledSep 30, 2026
- Lawsuit filed or ruledSep 30, 2026
- Amended attachment: Lawsuit filed or ruledSep 30, 2026
- [Corrected] Adjustment of Exercise Price for Share Subscription WarrantsSep 29, 2026
Titles in Korean until English translations are added.
Also known as: Dt&Cro / 디티앤씨알오 / 383930 / KRX:383930
Source: KRX statistical information